ICE T-TIMI 49 was a randomized, open-label, multicenter, placebo-controlled pilot study to evaluate the feasibility and safety of a 4mg IC TNK administered before and following PPCI with protocol-mandated aspirin, clopidogrel, unfractionated heparin, and intravenous glycoprotein IIb/IIIa inhibition.
